BioCentury
ARTICLE | Finance

Innovent’s Hong Kong spark

Why Innovent could see robust performance in Hong Kong where others have not

November 2, 2018 11:03 PM UTC

A strong performance out of the gate for Innovent Biologics Inc. (HKSE:1801) reflects investor confidence in the company’s pipeline regardless of market conditions.

The biologics company raised HK$3.3 billion ($421 million) in an IPO priced near the top of its proposed range on Oct. 23. The deal valued Innovent at $2 billion. ...